Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Gold Nanorods Help Fight Cancer

By HospiMedica staff writers
Posted on 29 Oct 2007
A new study has shown how tiny nanorods made of gold can be triggered by a laser beam to blast holes in the membranes of tumor cells, setting in motion a complex biochemical mechanism that leads to a tumor cell's self-destruction.

Researchers at the Weldon School of Biomedical Engineering at Purdue University (West Lafayette, IN, USA) conducted experiments with tumor cells in laboratory cultures, and took advantage of the fact that tumor cell membranes often have an abnormally high number of receptor sites to capture molecules of folic acid (folate). More...
The researchers then attached folate to gold nanorods, enabling them to target the receptors and attach themselves to the tumor cell membranes, from where they were eventually taken up into the cells.

The researchers found that by exposing the nanorods to laser-emitted near-infrared light while they were still on the membrane surface, the nanorods cause the formation of membrane blebs similar to severe blistering. The researchers discovered, however, that the blebbing was caused through a complex biochemical pathway, and not by the heat generated through the energy absorbed. Extra calcium enters the cell and triggers enzyme activity, which causes the infrastructure inside the cell to become loose, giving rise to the membrane blebs. The study was published in the October 19, 2007, edition of the journal Advanced Materials.

"We have found that rather than cooking the cells to death, the nanorods first punch holes in the membrane,” said co-author Alexander Wei, Ph.D., an associate professor of chemistry at Purdue. "This generates a plasma bubble that lasts for about a microsecond, in a process known as cavitation. Every cavitation event is like a tiny bomb. Then suddenly, you have a gaping hole where the nanorod was.”

The gold rods used were less than 15 nanometers wide and 50 nanometers long, or roughly 200 times smaller than a red blood cell. Their small size is critical for the technology's potential medical applications, since the human immune system quickly clears away particles larger than 100 nanometers, whereas smaller nanoparticles can remain in the bloodstream far longer.


Related Links:
Weldon School of Biomedical Engineering

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.